10.89
+1.02%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Novavax
From its filings with the US Securities and Exchange Commission
Novavax is based in Gaithersburg, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NVAX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $1.12bn and net income of $440.3m. At that date it held total assets of $1.18bn and shareholders' equity of −$127.8m. By region, Rest of North America accounted for 51.2%, followed by United States at 36.1% and Rest of the world at 11.3%.
Novavax, Inc., together with our wholly owned subsidiaries, tackles some of the world’s most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M™ adjuvant and protein-based nanoparticles.
Our corporate growth strategy focuses on maximizing the impact of our cutting-edge technology by forging partnerships for our Matrix-M adjuvant and research and development (R&D) assets while maintaining a lean and focused operating model.
Our technology platform, combined with our deep vaccine expertise, is the fuel for innovation and partnerships, and we believe it has the potential to create significant value. Our proprietary Matrix-M™ adjuvant when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Our recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Together, we believe that our technology platform can induce potent, durable and broad immune responses, with the potential to be antigen-sparing. Our Matrix-M™ adjuvant can increase both antibody and cell-mediated immune responses to the vaccine and it has demonstrated a favorable tolerability profile in clinical trials. Our technology platform is used in our authorized COVID-19 Vaccine (Nuvaxovid) and the R21/Matrix-M™ adjuvant malaria vaccine (as defined below).
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Sept 2001
- Employees
- 749
- Website
- novavax.com ↗
- Head office
- 21 FIRSTFIELD RD, GAITHERSBURG, MD
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Margaret McglynnIndependent Chairman of the Board$466,082
- Mr. John JacobsPresident, Chief Executive Officer, Director, since 2023$5.1m
- Mr. James KellyChief Financial Officer, Executive Vice President, Treasurer$1.8m
- Mr. Mark CaseyExecutive Vice President, Chief Legal Officer, Company Secretary$1.1m
- Dr. Ruxandra Draghia-AkliExecutive Vice President, Head of Research & Development
- Ms. Elaine O'haraExecutive Vice President, Chief Strategy Officer$1.6m
- Dr. Robert WalkerSenior Vice President, Chief Medical Officer
- Mr. Gregg AltonIndependent Director$453,427
- Dr. Richard DouglasIndependent Director$470,614
- Ms. Rachel KingIndependent Director$456,114
- Mr. David MottIndependent Director$468,614
- Mr. Charles NewtonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 48
- Social
- 75
- Governance
- 21
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Novavax Inc has a diverse portfolio of vaccine candidates covering various diseases.
- Their technology platform, recombinant nanoparticle, has shown promising results in preclinical and clinical trials.
- The company has a strong research and development team with extensive expertise in vaccine development.
- Novavax has established collaborations with global organizations, enhancing their reach and market presence.
Weaknesses
- Novavax Inc has experienced delays in their product development timelines, which may impact their competitive advantage.
- The company is heavily reliant on successful clinical trials and regulatory approvals for their vaccine candidates.
- Novavax faces potential competition from other vaccine developers in the market.
Opportunities
- The growing demand for vaccines, especially during global health crises, presents significant opportunities for Novavax.
- Expanding their vaccine portfolio to cover emerging diseases could open new markets and revenue streams for the company.
- Collaborating with governments and international organizations to address global health challenges can lead to partnerships and funding opportunities.
Threats
- The unpredictable nature of disease outbreaks and pandemics could impact Novavax's ability to timely develop and distribute vaccines.
- Competition in the vaccine industry is intense, with established players and new entrants continuously emerging.
- Regulatory challenges and potential adverse events related to vaccines may hinder market acceptance and revenue generation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.